References
- Crooke ST. Comprehensive reform of the new drug regulatory process. BioTechnology 1995;13:25–29.
- Mathieu M. New drug development: a regulatory overview. Cambridge, MA: Parexel International Corp.; 1990.
- Peck G.E. The food and drug laws which affect drug product design, manufacture, and distribution. In: Banker GS, Rhodes CH, editors. Modern pharmaceuticals. New York: Marcel Dekker; 1979. p 735.
- Spivey RN, Lasagna L, Trimble AG. New drug applications: how long to gain approval? Clinical Pharm Therap 1985;37:361.
- Eichler H. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Disc 2008;7:818–826.
- Dagher R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst 2004;96:1500–1509.
- EMEA. Committee for Medicinal Products for Human Use (CHMP). Guideline on the scientific application and the practical arrangements necessary to implement commission regulation (EC) No 507–2006 on the conditional marketing authorization for medicinal products for humane use falling within the scope of regulation (EC) No 726/2004. EMA website 2006. Available online at: http://www.emea.europa.eu/pdfs/human/regaffairs/50995106en.pdf, accessed
- FDA. Fast track accelerated approval and priority review. Accelerating availability of new drugs for patients with serious diseases. FDA website 2006. Available online at: http://www.fda.gov/oashi/fast.html, accessed